商务部新闻发言人就欧盟拟限制中企参与医疗器械公共采购答记者问；乐普医疗“童颜针”获批丨医药早参

Group 1 - The European Union plans to restrict Chinese companies' participation in public procurement of medical devices, reflecting an escalation in economic friction between China and Europe in the high-end manufacturing sector [1] - The Chinese Ministry of Commerce emphasizes the importance of adhering to WTO rules and maintaining fair competition principles, urging the EU to correct its actions and expressing a commitment to protect the legitimate rights of Chinese enterprises [1] Group 2 - Lepu Medical announced that its self-developed polylactic acid facial filler, known as "童颜针" (Youthful Needle), has received registration approval from the National Medical Products Administration (NMPA), marking a significant milestone for the company in the dermatology field [2] - The approval allows Lepu Medical to enter the competitive medical aesthetics market, potentially providing new growth opportunities, although the market already has several similar products, raising concerns about product homogeneity and the need for validation of clinical performance and brand strength [2] Group 3 - Huaxi Biological responded to recent controversies regarding "recombinant collagen," clarifying that its opposition is to the misuse of terminology rather than to collagen research and industrial transformation [3] - The company emphasizes the importance of product quality and seeks to address issues within the industry, highlighting the need for trust to be built on empirical data rather than concept misuse [3]